Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Phase 2 Completed 11 enrolled Stanford University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL

Timeline

Start: 2006-08
Primary completion: 2007-08
Completion: 2010-04

Publications

Results Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Apr;47(4):581-8. doi: 10.1038/bmt.2011.104. Epub 2011 May 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MMF	Unknown	15 mg/kg	Intravenous
Subject	Sirolimus	Small molecule	4 mg	Oral
Background	BU	Unknown	1 mg/kg	Intravenous
Background	CY	Unknown	45 mg/kg	Intravenous
Background	CY	Unknown	60 mg/kg	Intravenous
Background	CY	Unknown	100 mg/kg	Intravenous
Background	Etoposide	Small molecule	60 mg/kg	Intravenous
Background	carmustine	Small molecule	15 mg/kg	Intravenous

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Summary

Timeline

Publications

Drugs

Indications